Curesponse Overview

  • Founded
  • 2017
  • Status
  • Private
  • Employees
  • 12
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $6.16M
Latest Deal Amount
  • Investors
  • 3

Curesponse General Information


Developer of a three-dimensional tissue culture system designed for modeling cancer growth and drug response. The company's platform preserves the cancer tissue architecture including the vasculature and immune system accurately reflecting the cancer growth found in the body, enabling doctors to determine drug response for a specific individual's tumor type.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Tel aviv Medical Center (TAMC)
  • Sammy Ofer Building, 10th Floor, 6 Weizmann Street
  • Tel Aviv
  • Israel

Curesponse Timeline

Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Curesponse Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 05-Jun-2020 $6.16M 00.000 000.00 Completed Generating Revenue
1. Seed Round 01-Aug-2018 00.00 00.00 00.000 Completed Startup
To view Curesponse’s complete valuation and funding history, request access »

Curesponse Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preferred A 0,000,000 00.0 00.0 00 00.0 00.000
Ordinary A 000,000 00.0 00.0 00 00.0 00.000
To view Curesponse’s complete cap table history, request access »

Curesponse Executive Team (4)

Name Title Board Seat Contact Info
Seth Salpeter Ph.D Co-Founder & Chief Technology Officer
Nancy Gavert Co-Founder
Ravid Straussman Ph.D Scientific Founder
Guy Neev Co-Founder & Chief Executive Officer
To view Curesponse’s complete executive team members history, request access »

Curesponse Board Members (1)

Name Representing Role Since
Yair Schindel MD aMoon Fund Chairman 000 0000
To view Curesponse’s complete board members history, request access »

Curesponse Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Curesponse Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
aMoon Fund Venture Capital Minority 000 0000 000000 0
NCL Technology Ventures Venture Capital Minority 000 0000 000000 0
Marius Nacht Angel (individual) Minority 000 0000 000000 0
To view Curesponse’s complete investors history, request access »